MedPath

The Prognosis of Colorectal Cancer Patients After Indocyanine Green Fluorescence-guided Radical Surgery

Completed
Conditions
Colorectal Cancer
Registration Number
NCT06508541
Lead Sponsor
Shanghai Tong Ren Hospital
Brief Summary

Previous studies of Indocyanine green (ICG) in colorectal surgery have focused on lymphatic mapping, lymph node detection, and the number of harvested lymph nodes. However, relatively few studies have evaluated the outcomes of this imaging technology, especially the prognosis following of colorectal cancer resection. The present study assessed the prognosis of colorectal cancer patients following ICG fluorescence-guided surgery as compared to conventional surgery without the use of ICG Fluorescence imaging

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
235
Inclusion Criteria

(1)age > 18 years, (2)confirmed diagnosis of primary CRC, (3)preoperative tumor stage of cT1 to cT4, N-/+, M0 as determined by contrast-enhanced computed tomography (CT), (4) no distant metastasis, and (5)American Society of Anesthesiologists(ASA)Physical Status Classification score of 1, 2, or 3-

Exclusion Criteria

(1) history of previous colorectal surgery, emergent surgery, or palliative resection;(2)pregnancy or breastfeeding;(3) allergy or history of an adverse reaction to ICG; and (4) severe mental disorder.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
disease-free survival(DFS)1 month

the duration from radical surgery to the confirmation of recurrence or metastasis by regular or telephone follow-up

Secondary Outcome Measures
NameTimeMethod
the number of harvested lymph nodes1month

the number of harvested lymph nodes including positive and negative ones

Trial Locations

Locations (1)

Shanghai Tongren Hospital

🇨🇳

Changning, Shanghai, China

Shanghai Tongren Hospital
🇨🇳Changning, Shanghai, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.